16 completed, 4 terminated, 4 unknown, 1 active not recruiting. 26 Phase 2, 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 16, Terminated 4, Unknown 4, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 11 | Completed 4, Unknown 4, Terminated 2, Active not recruiting 1 |
Follow Stage III Mantle Cell Lymphoma: new trials by email Literature Review of Stage III Mantle Cell Lymphoma trials Research Report on Stage III Mantle Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 anti-CD19/22-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-08-01 | 2019-04-17 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | AIDS Malignancy Consortium | 11 | 2016-06-23 | 2026-05-18 |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma anti-CD19 CAR-T, Fludarabine, Cyclophosphamide - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 20 | 2016-02-01 | 2017-03-16 |
| Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma CD19.CAR-T cells - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 1 / Phase 2 | Unknown | Xinqiao Hospital of Chongqing | 20 | 2015-12-01 | 2019-02-27 |
| Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma ibrutinib, laboratory biomarker analysis - Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma | Phase 2 | Completed | Northwestern University | 37 | 2015-01-12 | 2026-06-10 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy anti-CD20-CAR vector-transduced autologous T cells, genetically engineered lymphocyte therapy - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 50 | 2013-01-01 | 2015-09-29 |
| Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine - Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma | Phase 2 | Completed | Roswell Park Cancer Institute | 37 | 2011-12-06 | 2024-02-07 |
| Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation bortezomib, rituximab, laboratory biomarker analysis - Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 23 | 2011-10-03 | 2023-07-27 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload deferasirox - Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2010-07-01 | 2019-06-18 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer rituximab, mycophenolate mofetil, tacrolimus - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Terminated | University of Nebraska | 20 | 2009-12-10 | 2023-09-06 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant ondansetron, survey administration, management of therapy complications - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 49 | 2008-08-08 | 2017-05-23 |
| Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma vorinostat, rituximab, ifosfamide - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Completed | University of Washington | 29 | 2007-12-01 | 2017-05-25 |
| Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma bortezomib, rituximab, cyclophosphamide - Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 77 | 2007-05-01 | 2014-10-30 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer beclomethasone dipropionate, placebo, tacrolimus - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 140 | 2007-04-01 | 2021-02-03 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma fenretinide, rituximab - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2005-10-01 | 2014-10-06 |
Showing 20 of 26. Sign in to see all of them.
Lymphoma, Mantle-Cell (26) · Lymphoma, Follicular (21) · Lymphoma, Large B-Cell, Diffuse (20) · Leukemia, Lymphocytic, Chronic, B-Cell (19) · Burkitt Lymphoma (15) · Hodgkin Disease (15) · Lymphoma, B-Cell, Marginal Zone (15) · Lymphoma, Non-Hodgkin (15) · Lymphoma, Large-Cell, Immunoblastic (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Waldenstrom Macroglobulinemia (12) · Lymphoma, T-Cell, Cutaneous (11) · Mycosis Fungoides (11) · Sezary Syndrome (11) · Leukemia, Myeloid, Acute (10)
Hemic and Lymphatic Diseases (26) · Immune System Diseases (26) · Immunoproliferative Disorders (26) · Lymphatic Diseases (26) · Lymphoma (26) · Lymphoproliferative Disorders (26) · Neoplasms (26) · Neoplasms by Histologic Type (26) · Lymphoma, B-Cell (21) · Chronic Disease (19) · Disease Attributes (19) · Hematologic Diseases (19) · Leukemia (19) · Leukemia, B-Cell (19) · Leukemia, Lymphoid (19)
Rituximab (7) · Cyclophosphamide (6) · Mycophenolic Acid (6) · Tacrolimus (6) · Whole-Body Irradiation (6) · fludarabine phosphate (6) · Peripheral Blood Stem Cell Transplantation (5) · Cyclosporine (3) · Doxorubicin (3) · Etoposide (3) · Gene Expression Profiling (3) · Methotrexate (3) · Vincristine (3) · merphos (3) · Bortezomib (2)
Fred Hutchinson Cancer Center (7) · Chinese PLA General Hospital (3) · National Cancer Institute (NCI) (3) · City of Hope Medical Center (2) · Northwestern University (2) · AIDS Malignancy Consortium (1) · Burzynski Research Institute (1) · Roswell Park Cancer Institute (1) · The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine (1) · University of Chicago (1) · University of Nebraska (1) · University of Washington (1) · Wake Forest University Health Sciences (1) · Xinqiao Hospital of Chongqing (1)
United States (21) · China (5) · Italy (3) · Germany (2) · Denmark (1)
Brenda Sandmaier (3) · Adam Petrich, MD (1) · Ajay Gopal (1) · Barbara Pro, MD (1) · Bo Zhu, M.D., Ph.D. (1) · Brad Kahl (1) · David Maloney (1) · Francisco Hernandez-ILizaliturri (1) · Leona Holmberg (1) · Lihua Budde (1) · Mary Ann Knovich, MD (1) · Matthew Mei (1) · Mehrdad Abedi (1) · Paul Martin (1) · Paul O'Donnell (1)
PMID 32499241, PMID 34515338, PMID 19900571, PMID 24458437, PMID 25085357, PMID 25444722, PMID 25964296, PMID 29263894, PMID 29954415, PMID 32245502, PMID 35157306, PMID 37756532, PMID 40720747, PMID 41804087
P30CA015704 (4), P01CA018029 (3), P01CA078902 (1), P30CA014599 (1), P30CA036727 (1), P30CA046592 (1), P30CA060553 (1), R21CA119519 (1), U01CA121947 (1), U10CA021115 (1)